SubscribeLogin
Published

IceCure’s ProSense Cryoablation System’s Benefit-Risk Profile for Breast Cancer Indications Reviewed by FDA Panel - Endovascular Today

Summary by Endovascular Today
November 25, 2024—IceCure Medical Ltd. recently announced the FDA Medical Device Advisory Committee Panel’s favorable recommendation (voting, 9-5) of the benefit-risk profile of the company’s ProSense cryoablation system for the proposed indications of the treatment of patients with early-stage, low-risk invasive breast cancer with cryoablation and adjuvant endocrine therapy. The FDA’s decision on marketing authorization is expected in the first…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Francisco, CaliforniaSan Francisco, California
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal